Alta Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$443K Hold
991
0.16% 93
2025
Q4
$449K Sell
991
-280
-22% -$121K 0.16% 98
2025
Q3
$498K Hold
1,271
0.15% 108
2025
Q2
$566K Hold
1,271
0.2% 94
2025
Q1
$616K Buy
1,271
+400
+46% +$186K 0.26% 81
2024
Q4
$351K Buy
871
+171
+24% +$79.3K 0.22% 89
2024
Q3
$326K Hold
700
0.15% 79
2024
Q2
$328K Hold
700
0.16% 76
2024
Q1
$293K Hold
700
0.15% 84
2023
Q4
$285K Hold
700
0.15% 80
2023
Q3
$243K Hold
700
0.14% 88
2023
Q2
$246K Hold
700
0.14% 85
2023
Q1
$221K Hold
700
0.13% 93
2022
Q4
$202K Hold
700
0.12% 101
2022
Q3
$203K Buy
+700
New +$201K 0.13% 87

Other funds holding VRTX

Alta Advisers's VRTX Position: Q1 2026 in Review

Alta Advisers held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 991 shares worth $443K. The position accounts for 0.16% of the portfolio, ranked #93.

Alta Advisers first reported a position in VRTX in Q3 2022 and has held it in 15 quarters since. The position peaked at $616K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Alta Advisers held 991 shares of Vertex Pharmaceuticals worth $443K as of Q1 2026.
  • Alta Advisers left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.16% of Alta Advisers's portfolio in Q1 2026, its #93 holding.
  • Alta Advisers first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
  • Alta Advisers's Vertex Pharmaceuticals position peaked at $616K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Alta Advisers's 13F filing for Q1 2026, filed 7 May 2026.